Is S100B Involved in Attention-Deficit/Hyperactivity Disorder (ADHD)? Comparisons with Controls and Changes Following a Triple Therapy Containing Methylphenidate, Melatonin and omega-3 PUFAs
Metadatos
Afficher la notice complèteEditorial
MDPI
Materia
ADHD S100B Attention Methylphenidate Melatonin omega-3 PUFAs
Date
2023-01-31Referencia bibliográfica
Ouadih-Moran, M... [et al.]. Is S100B Involved in Attention-Deficit/Hyperactivity Disorder (ADHD)? Comparisons with Controls and Changes Following a Triple Therapy Containing Methylphenidate, Melatonin and!-3 PUFAs. Nutrients 2023, 15, 712. [https://doi.org/10.3390/nu15030712]
Résumé
Background: Increasing evidence supports a neuroinflammatory basis in ADHD damaging
glial function and thereby altering dopaminergic (DA) neurotransmission. Previous studies
focusing on the S100B protein as a marker of glial function have shown contradictory results. We
conducted a clinical trial to investigate differences in S100B levels between ADHD patients and
controls, as well as observe gradual changes in S100B concentrations after a triple therapy (TT) containing
methylphenidate (MPH), melatonin (aMT) and omega-3 fatty acids (!-3 PUFAs). Methods:
62 medication-naïve children with ADHD (ADHD-G) and 65 healthy controls (C-G) were recruited.
Serum S100B was measured at baseline (T0) in ADHD-G/C-G, and three (T3) and six months (T6)
after starting TT in the ADHD-G, together with attention scores. Results: A significant increase in
S100B was observed in the ADHD-G vs. C-G. In the ADHD-G, significantly higher S100B values
were observed for comparisons between T0–T3 and between T0–T6, accompanied by a significant
improvement in attention scores for the same timepoint comparisons. No significant differences were
found for S100B between T3–T6. Conclusion: Our results agree with the hypothesis of glial damage
in ADHD. Further studies on the link between DA and S100B are required to explain the transient
increase in S100B following TT.